Moderna Jumps 6.3% as Revenue Growth Accelerates and 2026 Outlook Improves

Moderna (NASDAQ: MRNA) shares rose about 6.3% after the company reported stronger third-quarter results, raised its 2026 revenue outlook and improved its expected year-end cash position.

Third-quarter revenue increased 29% year over year to $1.3 billion, while net income reached $162 million, or $0.38 per share, compared with a $200 million loss a year earlier. :chatgpt-content-reference{index="0"}

Moderna now expects full-year 2026 revenue growth of 15%-25%, up sharply from its prior expectation of up to 10%. The company also lowered expected R&D spending to about $2.7 billion from $2.9 billion. :chatgpt-content-reference{index="1"}

Year-end cash and investments are now projected at $8.1-$8.3 billion, compared with the previous outlook of $4.7-$5.2 billion, helped by better operating execution and proceeds from a convertible notes offering. :chatgpt-content-reference{index="2"}

Pipeline momentum also remained supportive, including FDA approval of mFLUSIVA and positive Phase 3 melanoma results for intismeran in combination with Keytruda. :chatgpt-content-reference{index="3"}

The 6.3% share gain appears to reflect the stronger revenue trajectory, improved cost outlook and substantially higher cash guidance, alongside progress in Moderna’s respiratory and oncology pipeline.